SCHEMBL5362873

SCHEMBL5362873

CC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)CC1OC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
LMNA P02545 3/20 0.45
PDE3A Q14432 3/20 0.45
CACNA1F O60840 2/20 0.45
ALB P02768 2/20 0.45
MAPT P10636 2/20 0.45
CACNA1D Q01668 2/20 0.45
CACNA1S Q13698 2/20 0.45
CACNA1C Q13936 2/20 0.45
POLG P54098 2/20 0.43
THRB P10828 1/20 0.42
MTOR P42345 1/20 0.42
MDM2 Q00987 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
P2RY2 P41231 3/20 0.41
P2RY4 P51582 3/20 0.41
P2RY6 Q15077 2/20 0.41
POLA1 P09884 1/20 0.41
PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362913 1.00 POLB (0.49) POLBLMNAPDE3ACACNA1FALB
SCHEMBL1763168 0.89 POLB (0.55) POLBLMNAPDE3ACACNA1FALB
SCHEMBL1763169 0.89 POLB (0.55) POLBLMNAPDE3ACACNA1FALB
SCHEMBL8627864 0.87 POLB (0.63) POLBLMNAPDE3ACACNA1FALB
SCHEMBL2582769 0.86 POLB (0.52) POLBLMNATHRBP2RY2P2RY4
SCHEMBL5180509 0.85 POLB (0.46) POLBLMNAPDE3ACACNA1FALB
SCHEMBL9999640 0.84 DNMT1 (0.56) POLBLMNAMAPTTHRBMTOR
SCHEMBL118663 0.84 DNMT1 (0.56) POLBLMNAMAPTTHRBMTOR
SCHEMBL13376153 0.84 DNMT1 (0.56) POLBLMNAMAPTTHRBMTOR
SCHEMBL10063813 0.84 DNMT1 (0.56) POLBLMNAMAPTTHRBMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014022839-A1 EXOCYLIC NITROGEN ATOM PROTECTED NUCLOSIDE AND METHOD FOR PRODUCING AND USING THE SAME THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-02-06 WO disclosed
US-7169765-B1 Acyl deoxyribonucleoside derivatives and uses thereof WELLSTAT THERAPEUTICS CORPORATION (US) 2007-01-30 US disclosed
US-20040192635-A1 Acyl deoxyribonucleoside derivatives and uses thereof WELLSTAT THERAPEUTICS CORPORATION (US) 2004-09-30 US disclosed
US-6743782-B1 ACYL DERIVATIVE OF 2'-DEOXYADENOSINE; TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED CELLULAR DAMAGE, IMPROVING WOUND HEALING AND TISSUE REPAIR, AMELIORATING THE EFFECTS OF AGING; ENHANCE BIOAVAILABILITY WELLSTAT THERAPEUTICS CORPORATION 2004-06-01 US disclosed
EP-0712629-B1 Acyl deoxyribonucleoside derivatives and uses thereof WELLSTAT THERAPEUTICS CORP (US) 2003-06-18 EP disclosed
US-6348451-B1 WOUND HEALING AGENTS FOR ANIMALS PRO-NEURON, INC. 2002-02-19 US disclosed
US-6306834-B1 METHODS OF TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR, COMPRISING ADMINISTERING THE COMPOSITIONS OF THE PRESENT INVENTION TO AN ANIMAL. PRO-NEURON, INC. 2001-10-23 US disclosed
US-6297222-B1 TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, AND METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR PRO-NEURON, INC. 2001-10-02 US disclosed
US-6103701-A ADMINISTERING COMPOSITIONS COMPRISING ACYL DERIVATIVES OF 2'-DEOXYRIBONUCLEOSIDES; FOR IMPROVING WOUND HEALING AND TISSUE REPAIR VON BORSTEL REID WARREN (US) 2000-08-15 US disclosed
US-6020322-A Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 2000-02-01 US disclosed
US-6020320-A Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 2000-02-01 US disclosed
EP-0355131-B1 ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF PRO NEURON INC (US) 1996-09-04 EP disclosed
EP-0712629-A1 Acyl deoxyribonucleoside derivatives and uses thereof PRO-NEURON, INC. (US) 1996-05-22 EP disclosed
EP-0355131-A1 ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF PRO-NEURON, INC. (US) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192635-A1 Acyl deoxyribonucleoside derivatives and uses thereof UNG, OGG1, NQO1 POLB 46/4885LMNA 587/4885PDE3A 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.